# Tenet Healthcare Corporation (THC) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $265.05, market value $21.3 billion.

## Valuation
- **P/E (trailing): 10.2×** (5-yr avg 10.5×, 3-yr avg 10.0×). Tenet Healthcare Corporation trades at 10.2× trailing earnings, close to its own five-year average of 10.5×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 12.6×, higher than trailing, so analysts expect earnings to fall.
- **Price / sales: 1.0×**. Each dollar of revenue is priced at 1.0×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 4.6×**. The shares trade at 4.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 5.8×**. Enterprise value is 5.8× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 14.2%** (5-yr avg 12.0%). Free cash flow equals 14.2% of the market value, in line with its five-year average of 12.0%. Above 5% is generally attractive.
- **Earnings yield: 9.8%**. The inverse of the P/E: 9.8% of the price is earned each year.

## Profitability
- **Operating margin: 20.8%**. 20.8% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 11.1%**. 11.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 56.1%**. A 56.1% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 24.7%**. Return on all capital, debt included, is 24.7%: comfortably above what that capital costs.
- **Return on assets: 10.7%**. Each dollar of assets produces 10.7% of profit.

## Growth
- **Revenue growth (1 yr): 3.1%** (3-yr 3.6%/yr, 5-yr 3.9%/yr). Revenue grew 3.1% over the last year, against 3.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -52.6%** (3-yr 59.9%/yr, 5-yr 32.8%/yr). Earnings per share fell 52.6%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 99.0%/yr**. Free cash flow has compounded at 99.0% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 3.12**. Debt is 3.12 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 1.9×**. It would take 1.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 1.76** (quick 1.76). Current assets cover the next year's liabilities 1.76 times.
- **Altman Z-score: 2.06**. A Z-score of 2.06 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Tenet Healthcare Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (21 analysts). 21 analysts cover Tenet Healthcare Corporation; the consensus is strong_buy, with an average price target of $285.10 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 37.7%** (YTD 33.4%, 3-mo 63.6%). The shares are up 37.7% over twelve months including dividends.
- **From 52-week high: -6.4%** (68.2% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.52** (volatility 43%). Beta of 0.52 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=THC · Page: https://foliofundamentals.com/stocks/thc

Not investment advice.